TriangleGilteritinib (NCT06225427)
Gilteritinib trial for Lung Non-Small Cell Carcinoma (NCT06225427). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for stage 4 ALK positive non small cell lung cancer that has progressed on other treatments, in adults.
The idea: reuse an approved drug. Gilteritinib is already FDA approved for a specific type of leukemia. The record says studies using ALK positive lung cancer cells showed activity against cells resistant to ALK drugs. Patients take it by mouth in 21 day cycles.
This phase 1 trial plans 30 patients and studies safety and the best dose. At the University of Michigan in Ann Arbor, Angel Qin leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.